ATE198149T1 - Verfahren zur stabilisierung von duocarmycinderivaten - Google Patents
Verfahren zur stabilisierung von duocarmycinderivatenInfo
- Publication number
- ATE198149T1 ATE198149T1 AT95918749T AT95918749T ATE198149T1 AT E198149 T1 ATE198149 T1 AT E198149T1 AT 95918749 T AT95918749 T AT 95918749T AT 95918749 T AT95918749 T AT 95918749T AT E198149 T1 ATE198149 T1 AT E198149T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- duocarmycin derivatives
- stabilizing
- sec
- image
- Prior art date
Links
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical class COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 title abstract 4
- 230000000087 stabilizing effect Effects 0.000 title 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003792 electrolyte Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000005846 sugar alcohols Polymers 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Detergent Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6106415A JPH07309761A (ja) | 1994-05-20 | 1994-05-20 | デュオカルマイシン誘導体の安定化法 |
PCT/JP1995/000962 WO1995031971A1 (en) | 1994-05-20 | 1995-05-19 | Method for stabilizing duocarmycin derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE198149T1 true ATE198149T1 (de) | 2001-01-15 |
Family
ID=14433044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95918749T ATE198149T1 (de) | 1994-05-20 | 1995-05-19 | Verfahren zur stabilisierung von duocarmycinderivaten |
Country Status (17)
Country | Link |
---|---|
US (1) | US5703080A (de) |
EP (1) | EP0754030B1 (de) |
JP (1) | JPH07309761A (de) |
CN (1) | CN1148805A (de) |
AT (1) | ATE198149T1 (de) |
AU (1) | AU2455195A (de) |
BR (1) | BR9507640A (de) |
CA (1) | CA2190635A1 (de) |
CZ (1) | CZ338696A3 (de) |
DE (1) | DE69519667T2 (de) |
FI (1) | FI964624A (de) |
HU (1) | HUT78072A (de) |
NO (1) | NO964813D0 (de) |
NZ (1) | NZ285450A (de) |
PL (1) | PL317229A1 (de) |
SK (1) | SK148496A3 (de) |
WO (1) | WO1995031971A1 (de) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3532895A (en) * | 1994-09-30 | 1996-04-26 | Kyowa Hakko Kogyo Co. Ltd. | Antitumor agent |
EP1383544A4 (de) * | 2001-04-09 | 2007-12-12 | Progenics Pharm Inc | Anti-cd19-immunotoxine |
US7087600B2 (en) | 2001-05-31 | 2006-08-08 | Medarex, Inc. | Peptidyl prodrugs and linkers and stabilizers useful therefor |
ZA200507752B (en) * | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
NZ550934A (en) | 2004-05-19 | 2010-05-28 | Medarex Inc | Chemical linkers and conjugates thereof |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
KR101335798B1 (ko) | 2005-02-15 | 2013-12-02 | 듀크 유니버시티 | 항-cd19 항체 및 종양학에서 이의 용도 |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
JP5047947B2 (ja) | 2005-05-05 | 2012-10-10 | デューク ユニバーシティ | 自己免疫疾患のための抗cd19抗体治療 |
SI1896040T1 (sl) | 2005-06-29 | 2012-12-31 | Threshold Pharmaceuticals, Inc. | Fosforamidatna alkilatorska predzdravila |
CA2623652C (en) | 2005-09-26 | 2013-11-26 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
EP1940789B1 (de) | 2005-10-26 | 2011-11-23 | Medarex, Inc. | Verfahren und verbindungen zur herstellung von cc-1065-analoga |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
US8389688B2 (en) | 2006-03-06 | 2013-03-05 | Aeres Biomedical, Ltd. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
NZ578064A (en) | 2006-12-01 | 2012-01-12 | Medarex Inc | Human antibodies that bind cd22 and uses thereof |
CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
CA2672468A1 (en) | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
EP2114157B1 (de) * | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Phosphoramidatalkylator-prodrug für die krebstherapie |
TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
KR20090122439A (ko) | 2007-02-21 | 2009-11-30 | 메다렉스, 인코포레이티드 | 단일 아미노산을 갖는 화학적 링커 및 이의 접합체 |
EP2737907A3 (de) | 2007-05-07 | 2014-11-05 | MedImmune, LLC | Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen |
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
WO2009026274A1 (en) | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
US8268970B2 (en) | 2007-10-01 | 2012-09-18 | Bristol-Myers Squibb Company | Human antibodies that bind mesothelin, and uses thereof |
JP5490714B2 (ja) * | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | タンパク質製剤 |
CA2707443A1 (en) * | 2007-11-30 | 2009-06-11 | Bristol-Myers Squibb Company | Conjugates of anti-rg-1 antibodies |
US8192738B2 (en) | 2008-09-19 | 2012-06-05 | Medimmune, Llc | Targeted antibodies directed to DLL4 |
EP2344478B1 (de) | 2008-11-03 | 2017-09-27 | Syntarga B.V. | Cc-1065 analoga und ihre konjugate |
CN102438652B (zh) | 2008-11-12 | 2014-08-13 | 米迪缪尼有限公司 | 抗体制剂 |
AU2009331528A1 (en) | 2008-12-23 | 2011-08-11 | Astrazeneca Ab | Targeted binding agents directed to alpha5beta1 and uses thereof |
BRPI1015234A2 (pt) | 2009-06-22 | 2018-02-20 | Medimmune Llc | regiões fc projetadas para conjugação sítio específica. |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011047083A1 (en) | 2009-10-13 | 2011-04-21 | Oxford Biotherapeutics Ltd. | Antibodies against epha10 |
CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
AR080154A1 (es) | 2010-02-10 | 2012-03-14 | Immunogen Inc | Anticuerpos cd20 y su utilizacion |
NO3056203T3 (de) | 2010-04-21 | 2018-05-12 | ||
EP2598530A2 (de) | 2010-07-29 | 2013-06-05 | Xencor, Inc. | Antikörper mit modifizierten isoelektrischen punkten |
EP3828205A1 (de) | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1-antikörper |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
ES2640960T3 (es) | 2011-06-28 | 2017-11-07 | Oxford Biotherapeutics Ltd. | Anticuerpos para ADP-ribosil ciclasa 2 |
DK2766392T3 (da) | 2011-10-10 | 2019-10-07 | Xencor Inc | Fremgangsmåde til oprensning af antistoffer |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
CN105051069B (zh) | 2013-01-14 | 2019-12-10 | Xencor股份有限公司 | 新型异二聚体蛋白 |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
CA2897987A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
JP6594855B2 (ja) | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | ヘテロ二量体タンパク質 |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
AU2014232416B2 (en) | 2013-03-15 | 2017-09-28 | Xencor, Inc. | Modulation of T Cells with Bispecific Antibodies and FC Fusions |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10081682B2 (en) | 2013-10-11 | 2018-09-25 | Oxford Bio Therapeutics Ltd. | Conjugated antibodies against LY75 for the treatment of cancer |
ES2687225T3 (es) | 2014-01-10 | 2018-10-24 | Synthon Biopharmaceuticals B.V. | Método de purificación de conjugados anticuerpo-fármaco unidos a Cys |
CN114262344A (zh) | 2014-02-28 | 2022-04-01 | 杭州多禧生物科技有限公司 | 带电荷链接体及其在共轭反应上的应用 |
EA201691925A1 (ru) | 2014-03-28 | 2017-06-30 | Ксенкор, Инк. | Биспецифические антитела, которые связываются с cd38 и cd3 |
GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
AU2015292326A1 (en) | 2014-07-24 | 2017-02-23 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
PE20171103A1 (es) | 2014-11-26 | 2017-08-07 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38 |
BR112017011092A2 (pt) | 2014-11-26 | 2017-12-26 | Xencor Inc | anticorpos heterodiméricos que ligam cd3 e antígenos de tumor |
WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
CA2991973C (en) | 2015-07-12 | 2021-12-07 | Suzhou M-Conj Biotech Co., Ltd. | Bridge linkers for conjugation of a cell-binding molecule |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
US10227410B2 (en) | 2015-12-07 | 2019-03-12 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
MX2018015592A (es) | 2016-06-14 | 2019-04-24 | Xencor Inc | Anticuerpos inhibidores de puntos de control biespecificos. |
JP7021127B2 (ja) | 2016-06-28 | 2022-02-16 | ゼンコア インコーポレイテッド | ソマトスタチン受容体2に結合するヘテロ二量体抗体 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
MX2019004327A (es) | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
KR20220150408A (ko) | 2016-11-14 | 2022-11-10 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
JP2021506291A (ja) | 2017-12-19 | 2021-02-22 | ゼンコア インコーポレイテッド | 改変されたil−2 fc融合タンパク質 |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
CA3097741A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
SG11202010163QA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
US11530274B2 (en) | 2018-07-02 | 2022-12-20 | Amgen Inc. | Anti-STEAP1 antigen-binding protein |
EP3861016A2 (de) | 2018-10-03 | 2021-08-11 | Xencor, Inc. | Il-12-heterodimere fc-fusionsproteine |
CN114173875A (zh) | 2019-03-01 | 2022-03-11 | Xencor股份有限公司 | 结合enpp3和cd3的异二聚抗体 |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5084468A (en) * | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
JP2510335B2 (ja) * | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Dc―88a誘導体 |
KR910014122A (ko) * | 1990-01-19 | 1991-08-31 | 디께다 가즈히꼬 | 에토포시드-2-디메틸아미노 화합물의 동결건조 제제 |
US5214065A (en) * | 1990-06-11 | 1993-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Dc-89 derivatives |
JPH0669954B2 (ja) * | 1990-12-07 | 1994-09-07 | 吉富製薬株式会社 | 抗腫瘍組成物 |
EP0499130A1 (de) * | 1991-02-15 | 1992-08-19 | Kyowa Hakko Kogyo Co., Ltd. | Derivate der Verbindung DC-89 |
JP3608802B2 (ja) * | 1991-09-20 | 2005-01-12 | 第一サントリーファーマ株式会社 | 安定なカルシトニン医薬組成物及びその製造法 |
-
1994
- 1994-05-20 JP JP6106415A patent/JPH07309761A/ja active Pending
-
1995
- 1995-05-19 WO PCT/JP1995/000962 patent/WO1995031971A1/en active IP Right Grant
- 1995-05-19 AT AT95918749T patent/ATE198149T1/de not_active IP Right Cessation
- 1995-05-19 BR BR9507640A patent/BR9507640A/pt not_active Application Discontinuation
- 1995-05-19 NZ NZ285450A patent/NZ285450A/en unknown
- 1995-05-19 CZ CZ963386A patent/CZ338696A3/cs unknown
- 1995-05-19 AU AU24551/95A patent/AU2455195A/en not_active Abandoned
- 1995-05-19 CA CA002190635A patent/CA2190635A1/en not_active Abandoned
- 1995-05-19 PL PL95317229A patent/PL317229A1/xx unknown
- 1995-05-19 EP EP95918749A patent/EP0754030B1/de not_active Expired - Lifetime
- 1995-05-19 CN CN95193164A patent/CN1148805A/zh active Pending
- 1995-05-19 DE DE69519667T patent/DE69519667T2/de not_active Expired - Fee Related
- 1995-05-19 HU HU9603521A patent/HUT78072A/hu unknown
- 1995-05-19 US US08/737,145 patent/US5703080A/en not_active Expired - Fee Related
- 1995-05-19 SK SK1484-96A patent/SK148496A3/sk unknown
-
1996
- 1996-11-13 NO NO964813A patent/NO964813D0/no unknown
- 1996-11-19 FI FI964624A patent/FI964624A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
FI964624A0 (fi) | 1996-11-19 |
DE69519667D1 (de) | 2001-01-25 |
NO964813L (no) | 1996-11-13 |
BR9507640A (pt) | 1997-08-19 |
WO1995031971A1 (en) | 1995-11-30 |
MX9605694A (es) | 1998-05-31 |
CN1148805A (zh) | 1997-04-30 |
JPH07309761A (ja) | 1995-11-28 |
US5703080A (en) | 1997-12-30 |
AU2455195A (en) | 1995-12-18 |
HU9603521D0 (en) | 1997-03-28 |
SK148496A3 (en) | 1997-06-04 |
FI964624A (fi) | 1996-11-19 |
CZ338696A3 (en) | 1997-05-14 |
HUT78072A (hu) | 1999-08-30 |
NO964813D0 (no) | 1996-11-13 |
CA2190635A1 (en) | 1995-11-30 |
EP0754030A1 (de) | 1997-01-22 |
DE69519667T2 (de) | 2001-04-26 |
NZ285450A (en) | 1997-02-24 |
EP0754030B1 (de) | 2000-12-20 |
PL317229A1 (en) | 1997-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE198149T1 (de) | Verfahren zur stabilisierung von duocarmycinderivaten | |
ATE260658T1 (de) | Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen | |
ATE215371T1 (de) | Naphthyl substituierte benzimidazolderivate als antikoagulantien | |
PL292095A1 (en) | Pesticides and method of obtaining them | |
KR950700894A (ko) | 탁솔 유도체(Taxol derivatives) | |
DE69418461D1 (de) | Neue 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazol-derivate | |
ATE156818T1 (de) | Polyfluoralkylthiopoly(ethylimidazolium)- verbindungen, verfahren zu ihrer herstellung und ihre verwendung als biozide mittel | |
AU699480B2 (en) | 2,2-Dichloroalkane carboxylic acids, processes for their production and pharmaceutical agents containing these | |
AU7700096A (en) | Novel 2,3,5-trimethyl-4-hydroxyanilide derivatives, their preparation and their application in therapeutics | |
KR960013370A (ko) | 트리글리세리드 과다 방지 조성물 | |
ATE247959T1 (de) | Nicht peptidische g-csf mimetika | |
EP0340754A3 (de) | Monopersulfate von Amino-(poly)percarbonsäuren | |
KR950700234A (ko) | β-페닐이소세린 및 그외 동족체를 제조하는 방법(Method for preparing β-phenylisoserine and analogues thereof) | |
EA199900754A1 (ru) | Способ получения замещенного тиазолидиндиона | |
AU5644296A (en) | Novel heterocyclic chemistry | |
DE69330601D1 (de) | Serotoninergische ergolin derivate | |
BR9610175A (pt) | Composto processo de preparação do composto composição farmacêutica e utilização do composto | |
ATE244224T1 (de) | Verfahren zur umwandlung von 2,4-dichlorpyridinen in 2-aryloxy-4-chlorpyridine | |
DE59509186D1 (de) | N-substituierte azabicycloheptan-derivate als neuroleptika usw. | |
DE3750267D1 (de) | Herstellung von Piperidinylcyclopentylheptensäure-Derivaten. | |
SE9001592D0 (sv) | A therapeutical composition | |
KR940021524A (ko) | 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법 | |
KR910011258A (ko) | 녹내장의 치료방법 | |
RU94033356A (ru) | Новые производные тетрагидронафталина, способ их получения, фармацевтический состав на их основе и способ его получения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |